Drug · Other

Pegfilgrastim

CI-DRUG-00000706Explore in graph →CHEMBL1201568 Approved

Regulatory

Approvals (27)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory27 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as PEXEGRA (DIN 02553945) under ATC L03AA13 PEGFILGRASTIM. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 9, 2025	health-canada-dpd
CA Health Canada	—	Marketed in Canada as NIOPEG (DIN 02546973) under ATC L03AA13 PEGFILGRASTIM. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Feb 12, 2025	health-canada-dpd
CA Health Canada	—	Marketed in Canada as LAPELGA (DIN 02529343) under ATC L03AA13 PEGFILGRASTIM. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Nov 28, 2022	health-canada-dpd

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 19 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	34	19	44	220	27	CA, EU, US	Jan 31, 2002	1999-09
Non-Hodgkin Lymphoma	Phase4	Phase 4	9	4	4	34	0	—	—	2002-06
Malignant Breast Neoplasm	Phase4	Phase 4	5	2	13	52	0	—	—	2001-10
Malignant Lung Neoplasm	Phase4	Phase 4	2	1	1	14	0	—

Curated evidence

Clinical evidence (0)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

Data not yet available

No curated evidence item mentions this therapy yet.

Clinical trials

Trials with this intervention (223)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 201–223 of 223 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00280787	Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim	completed	Phase 2	24	UNC Lineberger Comprehensive Cancer CenterOTHER	1	Feb 5, 2013	clinicaltrials
NCT00086944	Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma	completed

Molecule

Record

Kind: Other
Mechanism: Granulocyte colony stimulating factor receptor agonist
Targets: 1 gene
UNII: 3A58010674
Aliases: ARMLUPEG, B-12019, B12019, Cegfila, Cegfila (previously pegfilgrastim mundipharma), Chs-1701, DYRUPEG, Fulphila, FULPHILA, Fylnetra, FYLNETRA, Granulocyte colony-stimulating factor pegfilgrastim, Grasustek, Hsp-130, La-ep2006, LA EP 2006, LAPELGA, Lupifil-p, Msb-11455, Msb11455, MYL-1401H, NEULASTA, Neulasta sureclick, Neupopeg, NIOPEG, Nyvepria, NYVEPRIA, Peg-filgrastim, Pegfilgrastim, Pegfilgrastim apgf … (+25)

Data updated 2 days agoSource updated unknown

Identifiers

Codes (34)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L03AA13	PEGFILGRASTIM
DIN (Health Canada)	02249790